75N95020Q00229

Submitted by pluggern on
Post Date/ Solicitation Issue Date
Closing Response Date
Proposed Award Date
Project Title
Mouse pharmacokinetics for 8 compounds
Contracting Office
National Institute on Drug Abuse (NIDA)

Contact Points

Primary Contract Specialist

Kevin
Alvarez
kevin.alvarez@nih.gov
NAICS Code Number
541990
Mouse pharmacokinetics for 8 compounds
Small Business Size Standard
16.5M
FPDS Classification Code
R499
Estimated Period of Performance
TBD
Delivery of Goods
TBD
Set-Aside Status
Not Set Aside
Competition Status
Non-Competitive
Vendor Name
Pharmaron, Inc
Vendor Address
201 E. Jefferson Street, Louisville, KY, 40202-1246
Single-Sole Source Determination
I hereby determine that the item or service listed herein is available from only one source and competition is precluded for the reasons that there are no substitutes or alternatives available.
Background/Description of Requirement

The National Center for Advancing Translational Sciences (NCATS) is a translational science center that prides itself on its tremendously productive pipeline and is innovative in several ways. NCATS brings together a diverse range of scientists, including medicinal chemists, biologists, toxicologists, and engineers, to ultimately translate basic science into real products and services that help improve people’s lives. Included in this process is the development of unique chemical material as a probe to investigate the mechanisms of cancer and to potentially assist in the development of new methods of treating human disease.

NCATS is interested in obtaining pharmacokinetic exposure data for 8 compounds. The pharmacokinetic data from these compounds is of key interest into determining the biological effects of these molecules in-vivo.

  1. 8 compounds will be assessed in a pharmacokinetics study
    1. A N=3 will be utilized for each compound and each group
      1. Group 1 will be Female C57 Black 6 mice (N=3)
    2. 8 or more time points will be collected for each compound. These time points will be between 0 and 24 hours (inclusive).
    3. A single route of administration will be utilized for each compound
      1. The route of administration will be intra-peritoneal (IP) injection
    4. Two doses for each compound will be utilized in each group
      1. The doses will be 1 mg/kg and 5 mg/kg.
    5. A comprehensive pharmacokinetic report will be made indicating (but not limited to) the AUC and Cmax for each compound in both plasma and brain.
    6. Comprehensive tables listing each individual animal, and the plasma concentration of the compound(s) at the given time point will be listed.

Interested parties may identify in writing their interest and capability in response to this requirement. Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses must be received by closing date and must reference the announcement. Responses may be submitted electronically to the attention of the contract specialist. Fax responses will not be accepted.

All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.